Stocks and Investing Stocks and Investing
Tue, March 3, 2020
Mon, March 2, 2020
Fri, February 28, 2020
Thu, February 27, 2020

Alethia Young Reiterated (SRPT) at Buy with Increased Target to $217 on, Feb 27th, 2020


Published on 2024-10-26 22:43:52 - WOPRAI, Alethia Young
  Print publication without navigation


Alethia Young of Cantor Fitzgerald, Reiterated "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $211 to $217 on, Feb 27th, 2020.

Alethia has made no other calls on SRPT in the last 4 months.



There are 6 other peers that have a rating on SRPT. Out of the 6 peers that are also analyzing SRPT, 0 agree with Alethia's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with Alethia


  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $173 on, Tuesday, December 24th, 2019
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $200 on, Monday, December 23rd, 2019
  • Brian Skorney of "Baird" Maintained at Buy with Increased Target to $192 on, Friday, December 20th, 2019
  • Yun Zhong of "Janney Montgomery Scott" Maintained at Strong Buy with Increased Target to $175 on, Friday, December 13th, 2019
  • Joel Beatty of "Citigroup" Maintained at Strong Buy with Decreased Target to $167 on, Monday, November 18th, 2019
  • Whitney Ijem of "Guggenheim" Initiated at Strong Buy and Held Target at $183 on, Friday, November 1st, 2019